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A 190 kDa protein was purified from conditioned media of mouse marrow-deeived stromal cell (ST2) cultures treated with lE,25dihydroxyvitamin 
Ds (1u,2S(OW)~D3) and identified as the third component of mouse complement (C3). Northern and Western blot analysis revealed that the peoduc- 
tion of C3 by ST2 and primary osteoblastic cells was strictly dependent on lg,ZS(OH),D,, but the production by hepatocytes was not. Adding 
lu,ZS(OW),D~ together with mouse C3 antibody to bone marrow cultures greatly inhibited the formation of tartratc-resistant acid phosphatase 
(TRAP)-positive osteoclast-like multinucleated cells. Adding C3 alone induced no TRAP-positive cell formation. These results suggest hat. in bone 
tissues, C3 is specifically produced by osteoblasts in response to lcz,25(OIQD~ and somehow involved in inducing differentiation of bone marrow 
cells into osteoclasts in concert with other factors peoduced by osteoblasts in eesponse to lo1.2S(OH),Da. 
Complement C3; lor,25-Dihydroxyvitamin Dj; Osteoblastic ell 
1. INTRODUCTION 
It is well established that 11~~,25(0H)zD3, theactive 
form of vitamin DJ, induces bone resorption in two 
distinct ways; one is the recruitment of new osteoclasts 
and the other is the activation of quiescent osteoclasts 
[l-43. Osteoclasts are unique multinucleated cells pre- 
sent only in bone, with characteristics such as tartrate- 
resistant acid phosphatase (TRAP) activity, abundant 
calcitonin receptors and bone-resorbing activity [S-9]. 
We previously reported that osteoclast-like cells which 
satisfied the above criteria were formed in co-cultures 
of primary osteoblastic cells isolated from mouse 
calvaria and mouse spleen cells in the presence of 
lc~,24(OH)tD3 [lo]. Separate cultures of either 
osteoblastic cells or spleen cells induced no osteoclast- 
like cell formation [lo]. The primary osteoblastic cells 
could be substituted by mouse bone marrow-derived 
stromal cells (ST2) in inducing osteoclast-like cell for- 
mation in co-cultures with spleen cells [l 11, This in- 
dicates that osteoblastic cells or marrow-derived 
stromal cells are somehow involved in osteoclast dif- 
ferentiation. In this study, we found a 190 kDa protein 
produced by ST2 cells and primary osteoblastic cells 
treated with lo~,25(OH)zD~. The 190 kDa protein was 
unequivocally identified as the third component of 
mouse complement (C3). The possible biological 
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significance of the specific production of C3 by 
osteoblasts was also examined. 
2. MATERIALS AND METHODS 
2.1. Cells and ntirure 
ST2 cells (purchased from Riken Cell Bank, Tsukuba, Japan) and 
primary osteoblastic ells prepared from mouse calvaria were cultured 
overnight in a-minimal essential medium (cu-MEM) containing 10% 
fetal bovine serum (FBS) in 24-multiwell dishes, and further cultured 
for 3 days in 0.5 ml of methionine-free (Y-MEM containing 0.1% 
bovine serum albumin (BSA) and 2 &i of [“‘Slmethionine with and 
without lo-” M la,25(OH)~Da. Conditioned media were collected, 
and 20 pl of the media was heat-denatured and applied to 7.5010 SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing con- 
ditions. The methods of Laemmli [12] were followed with a minor 
modification. 
2.2. Purification and identification of rlre 190 kDa protein 
For purification of a protein present in conditioned medium of ST2 
cell cultures treated with la,24(OH)zD;, the cells were cultured for 3 
days in the presence of 10e8 M lol,2S(OH)zD3 in CX-MEM containing 
0.140 BSA, and 2 liter of conditioned media was collected. Purifica- 
tion was performed sequentially by DEAE-sepharose, hydroxyapatite 
colutnn chromatography and HPLC (fitted with DEAE-SPW), and 
the purified protein was finally applied to SDS-PAGE under a reduc- 
ing or a non-reducing condition. The proteins on the gels were stained 
with Coomassic brilliant blue and transferred onto lmmobilon 
(Millipore, Bedford, MA) by electro-blotting, and their N-terminal 
amino acid sequences were determined using a protein sequencer (Ap- 
plied Biosystems, model 470A, Foster, CA). 
2.3. Northern blot analysis 
ST2 cells, primary osteoblastic cells, and primary hepatocytes were 
cultured fat 2 days in the presence or absence of 10-s M 
la,25(OH)~D:; in (Y-MEM containing IOqo FBS and the total KNAs 
were extracted from the cells by the guanidine thiocyanate/CsCI 
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Fig. 1. The effect of 1~,2S(OH)~D, on the production of [“Slmethio- 
nine-labeled proteins by the mouse marrow-derived stromal cell line, 
STZ, and mouse primary osteoblastic cells. ST2 cells (lanes 2 and 3) 
and primary osteoblastic cells (lanes 4 and 5) were incubated for 3 
days in the absence (lanes 2 and 4) or presence (lanes 3 and 5) of IO-’ 
M l&25(DH)zD3 and proteins in the conditioned media were analyz- 
ed under a reducing condition on SDS-PAGE. Lane 1 indicates 
standard protein markers. The arrow indicates the 116 kDa protein. 
method [l3]. The RNAs were separated by electrophoresis on I% 
agarose gels containing 2.2 M formaldehyde, transferred to a nylon 
membrane, and hybridized with ‘“P-labeled cDNA probes encoding 
mouse C3 or tubulin. 
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Mouse bone marrow mononuclear cells (1.5 x 106/ml) were 
cultured in 24-multiwell dishes with an antibody against mouse C3 
(Cappel, West Chester, PA) at a final dilution of I/lOJ with or 
without IO-’ M la,25(OH)zD3 in 0.5 ml of cr-MEM containing 10070 
FBS. On day 4, 0.4 ml of the old medium was replaced with fresh 
medium. After the culturing, the adherent cells were washed, fixed 
and stained for TRAP, non-specific esterase (NSE) and alkaline 
phosphatase (ALP) activities, as reported previously [4]. 
2.5. Radioimnurnoossay of mouse C3 
The contents of C3 in conditioned media of cell cultures and in 
mouse serum and calvaria were determined by radioimmunoassay us- 
ing ‘2SI-labeled purified C3 and its polyclonal antibody. The sensitivi- 
ty for the assay was 1 ng/tube. For in vitro experiments, conditioned 
media of ST2 and bone marrow cell cultures treated for 3 days with 
and without 10-s M Ic~,25(OH)zD3 were used. For in vivo ex,. 
periments, vehicle (ethanol) or 500 ng of lar,25(OH)~D3 was injected 
once subcutaneously into vitamin D-deficient mice prepared by the 
methods of Suds et al. [ 141 and the serum and calvaria were prepared 
72 h after the injection. The calvaria was homogenized with 50 mM 
Tris-WC1 buffer (pH 7.4) and centrifuged, then the resulting superna- 
tant was used for the assay. 
3. RESULTS AND DIXXJSSION 
Fig. 1 shows the SDS-PAGE of proteins produced by 
ST2 cells and primary osteoblastic cells. ~cY,~~(OH)ZD~ 
greatly increased the production of a 116 kDa protein 
under a reducing condition by both ST2 sells and 
primary osteoblastic cells (Fig. 1). The 116 kDa protein 
was purified and applied to SDS-PAGE under a reduc- 
ing or a non-reducing condition. The apparent mole- 
cular weight of the protein isolated was 190 kDa under 
non-reducing conditions, and 116 and 65 kDa under 
reducing conditions (Fig. 2A). The N-terminal amino 
acid sequence of the 116 kDa protein (number I-10) 
was identical to that of the a-chain of mouse C3 except 
for number 8 which was not identified [14-181 (Fig. 
2B). The sequence of the 65 kDa protein (number l-71 
El 
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Fig. 2. SDS-PAGE (A) and the N-terminal amino acid sequences (8) of the purified protein. (A) The protein was applied to SDS-PAGE under 
non-reducing (lane 2) or reducing (lane 3) conditions with standard protein markers (lane I), and stained with Coomasie brilliant blue. (B) Eluted 
proteins (190, 116 and 65 kDa) from lanes 2 and 3 were subjected to a protein sequencer. The amino acid sequence of hepatic C3 previously reported 
is shown in parenthesis (12-15). The symbol X indicates an amino acid residue which was not identified. 
1 2 3 4 5 6 9 8 9 IO
SVQLMEWXMB 
SVQLMEWWMB) 
I PMYS I I 
I PMYS I I TPN) 
1 2 3 4 5 6 9 8 9 10 
%VQLXEXXXB 
DP XYSl I XPN 
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was idrncicai tu that of the P-chain of mouse C3 [ 15 I( 81 
(Fig. 2B). The 190 kDa protein obtained under non- 
reducing conditions gave two different N-terminal 
amino acid residues in each Edman degradation, which 
exactly coincided with those of the 116 and 65 kDa pro- 
teins (Fig. 2B). The 190 kDa protein immunoreasted 
with a polyclonal mouse 63 antibody (data not shown). 
The mRNA expression of C3 was greatly and specifical- 
ly increased by 1~~,25(OW)zD3 in both ST2 cells (Fig. 3, 
lanes 1 and 2) and primary osteoblastic cells (Fig. 3, 
lanes 3 and 4). This also confirms that the purified pro- 
tein is identical to mouse C3. 
It is known that more than 90% of the C3 present in 
the blood stream is supplied by the liver [lQ]. We ex- 
amined the mRNA expression of C3 in hepatocytes and 
its regulation by vitamin D. The mRNA expression by 
hepatocytes similarly occurred even in the absence of 
la,25(OH)~Dj (Fig. 3, lanes 5 vs 6). Also, the 
[35S]methionine-labeled 116 kDa band produced by 
hepatocytes appeared irrespective of the presence or 
absence of la,25(OH)zD3 (data not shown). These 
results indicate that the hepatic production of C3 is not 
regulated by IcY,%S(OH)~D~. This may be explained in 
part by the absence of la,25(OH)~D3 receptors in the 
liver [%O]. 
The biological significance of the C3 production by 
bone marrow-derived stromal cells and osteoblastic 
cells in response to la,25(OH)zD~ is most interesting. 
To address this issue, we examined the role of C3 in 
osteoclast-like cell formation using mouse marrow 
cultures. TRAP-positive multinucleated osteoclast-like 
cells were formed adjacent to the colonies of ALP- 
positive osteoblastic cells, when marrow cells were 
cultured with lor,25(OH)tD3 (Fig. 4B). We have 
reported that these TRAP-positive multinucleated cells 
have calcitonin receptors and bone-resorbing activity 
[4]. When a polyclonal antibody against mouse C3 
(goat IgG fraction) together with lc~,25(OH)zD3 was 
added, the formation of both ALP-positive osteoblastic 
c3 - 28s 
- 18% 
Fig. 3. The effect of loc,25(OH)zD~ on the mRNA expression of C3 
by ST2 cells (lanes 1 and 2), primary osteoblastic cells (lanes 3 and 4) 
and primary mouse hepatocytes (lanes 5 and 6). Cells were cultured 
for 2 days in the absence (lanes 1, 3 and 5) or presence (lanes 2, 4 and 
6) of lo-’ M la,25(OH)~Dl. The positions of C3 and tubulin are in- 
dicated as C3 and Tub, respectively. positive osteoblastic cells (2). 
Fig. 4. The effect of antibody against mouse C3 on TRAP-positive 
osteoclast-like cell formation in mouse bone marrow cultures. Mouse 
marrow cells were cultured for 8 days without (A) or with 10e8 M 
la,25(OH)tD3 (B), or with an antibody against C3, together with 
10-s M lo(,25(OH)rD3 (C). The arrows indicate TRAP-positive 
mononuclear and multinucleated osteoclast-like cells (3), typical 
NSE-positive monocyte-macrophages (W), and colonies of ALP- 
cell colonies and TRAP-positive multinucleated cells 
was greatly inhibited (Fig. 4C). Instead, numerous 
NSE-positive mono-nuclear cells, probably monocyte- 
macrophages, appeared (Fig. 4C). TRAP-positive cell 
formation was not inhibited by adding non-immune 
goat IgG fraction (data not shown). Adding purified C3 
alone induced no TRAP-positive cell formation. These 
results indicate the possibilities that C3 is one of the fac- 
tors produced by osteoblasts in response to 
lar,25(OH)&% and that C3 is somehow involved in 
determining the differentiation pathways of bone mar- 
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row cells into osteoclasts and monocyte-masrophages in 
concert with other la,25(OH)2D3-dependent factors. 
It is important to determine whether the vitamin D- 
dependent production of C3 by osteoblastic cells and 
marrow-derived stromal cells is biologically relevant to 
bone metabolism. The circulating level of C3 in mice 
was about 1.5 mg/ml, which was at least 500- to 
lOOO-fold higher than the C3 concentration in the con- 
ditioned media of ST2 cells and bone marrow cells 
treated with l~~,25(OH)tD3 for 3 days. However, when 
la,25(OH)zD3 was administered into vitamin D- 
deficient mice, the calvaria1 level of C3 greatly increas- 
ed [vitamin D-deficient mice, 0.18, 0.24 ng/mg protein 
(n= 2); Ia,25(0H)tD3+upplemented mice, 0.98, 0.90 
ng/mg protein (n = 2)], whereas the serum level was not 
changed [vitamin D-deficient mice, 1 A, 1.5 mg/ml 
(n = 2); lcz,%S(OH)2D3-supplemented mice, 1 S, 1.8 
mg/ml (n = 2)]. The reason why the bone C3 levels are 
not influenced by the extremely high circulating levels 
of C3 has to be elucidated in the future. 
In conclusion, C3 is a factor specifically produced by 
osteoblasts and marrow-derived stromal cells (ST2) in 
response to la,25(OH)2D3. The C3 in bone appears to 
be involved in determining the differentiation pathways 
of bone marrow sells into monocyte-macrophages and 
osteoclasts in concert with other factors produced by 
osteoblasts in response to 1~~,25(OH)2Dj. The precise 
role of C3 in osteoclast differentiation is under in- 
vestigation in our laboratory. 
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